PHS
SOPH icon

PFM Health Sciences’s SOPHiA GENETICS SOPH Stock Holding History

PFM Health Sciences’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-879,913
Closed -$2.31M – 97
2022
Q3 		$2.31M Sell
879,913
-886,149
-50% -$3.11M 0.08% 81
2022
Q2 		$6.39M Sell
1,766,062
-247,962
-12% -$1.26M 0.24% 70
2022
Q1 		$15.6M Buy
2,014,024
+61,872
+3% +$695K 0.58% 50
2021
Q4 		$27.5M Sell
1,952,152
-70,400
-3% -$1.04M 0.94% 45
2021
Q3 		$35.5M Buy
+2,022,552
New +$35.6M 1.04% 42

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GE
General Electric Evendale, Ohio $308M AUM 40.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PFM Health Sciences's SOPH Position: Q4 2022 in Review

PFM Health Sciences sold out of SOPHiA GENETICS (SOPH) in Q4 2022, closing a stake of 879,913 shares — an estimated $2.31M sold.

PFM Health Sciences first reported a position in SOPH in Q3 2021 and held it in 5 quarters. The position peaked at $35.5M in Q3 2021. 32 funds tracked by Wall St. Rank hold SOPH as of Q4 2022.

  • PFM Health Sciences reported no remaining SOPHiA GENETICS position as of Q4 2022 after selling out during the quarter.
  • PFM Health Sciences sold 879,913 SOPHiA GENETICS shares in Q4 2022, an estimated $2.31M.
  • PFM Health Sciences first reported a position in SOPHiA GENETICS in Q3 2021 and held it in 5 quarters.
  • PFM Health Sciences's SOPHiA GENETICS position peaked at $35.5M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q4 2022.

Based on PFM Health Sciences's 13F filing for Q4 2022, filed 14 Feb 2023.